nanother: integration of novel nanoparticle based technology for therapeutics and diagnosis of...

8/8/2019 Nanother: Integration of novel NANOparticle based technology for THERapeutics and diagnosis of different types of…

http://slidepdf.com/reader/full/nanother-integration-of-novel-nanoparticle-based-technology-for-therapeutics 1/4

Integration of novel NANOparticle based technologyfor THERapeutics and diagnosis of different types of cancer



Nanother aims to successfully transformpolymer nanomaterials into nanocarriers viabiofunctionalisation (the linking of antibodies& ligands for detection), the binding of tumourcells, and the linking, delivery and releaseof therapeutic agents to treat the targetedtumour cells.

Nanother aims to select the bestnanocarriers throughout the project byrigorously testing toxicity, biocompatibility,ef cacy and biodistribution as an integralpart of the selection process in order tocontinue developing only the most ef cient,biocompatible and least toxic nanoparticles.

The nanocarriers selected will be furtherdeveloped and scaled-up, giving futureexploitable nanoproducts.

The big C & the uture o combined diagnosis & therapyThe World Health Organisation estimates that over 11 million new cases of cancer are diagnosedand more than seven million people die of cancer worldwide each year. The recorded incidenceof cancer is set to increase rapidly, as new screening techniques accelerate the rate of diagnosisand the population ages. In addition to its impact on individual patients, cancer imposes a greateconomic burden upon society.

In vivo 3D MRI at 120 µm resolution of mouse hind limbs.

The main challenge for pharmaceutical biotechnology nowadays is to direct a drug or therapeuticagent speci cally to a target molecule, enzyme, cell or tissue. Cancer is one of the most extensiveand life-threatening pathologies in Europe, only surpassed by circulatory diseases so it is theperfect candidate pathology for the development of new drugs and new tools for therapy anddiagnosis. There are many therapeutic agents that show activity in vitro, but when introduced inthe human body they do not have the same effect due to the limitation of reaching speci cally thetarget location, resulting in very high dosages given to patients to overcome this problem, leadingto problems of side effects.

Main ObjectivesNanother intersects biomedical, health and nano industries, and R&D sits at the interface of chemical, biological and physical sciences and engineering. The main Nanother objective istherefore based on the integration of 5 key elements of current technology:

Nanoparticle functionalisation technology,contrast agent & speci c antibody diagnostic techniques & imaging equipment,novel drug-delivery & activation systems

new uses for electromagnetic based technology and medical equipment. Another important innovation is RNAi technology, and the objective is to investigate the successfulformulation and application of nanocarriers including siRNA as the therapeutic agent.

T1-weighted MRI with 3orthogonal slices showing

the left femur and tibia ofa mouse.

Reproduction of the sagittalslice with image segmenta-

tion, allowing visualizationof tumor implantation site.

Courtesy of Magnetic Resonance Center, UMR 5536, Bordeaux, France



NANOTHER - Functional nanocarrier system for tumour diagnosis & therapy

NANOTHERPert Diagram

Methodology & work-fow

NANOTHER R&D Chain

Nanoparticles (polymer micelle & magnetic)

Targeting => Antibody & ligand (production & linkage)

Imaging => visualisation of targeted NP (MRI, SPECT, PET...)

Therapy => Drug compounds (loading mode, release mode...)

Theranostics => combined diagnostic & therapeutic approach

Testing of functionalised nanoparticles => breast, colon & bone cancer(texicology & biocompatibility, efficiency & biodistribution)

Concept Development Scale-upLaboratory(in vitro / in vivo)

The NANOTHER consortium

brings together 18 multi-

disciplinary partners from 9

European countries, and is

based on high-level scientifc

expertise from Universities,

Research Centres, SMES &

larger industry groups.

KEY : Fluorescent molecule Therapeutic agentdrug compound or siRNA

Antibody Magnetic core Polymer/coating

1) FUNCTIONALNANOCARRIERtargets tumour cells

2) DIAGNOSIS oftumour cell presenceby imaging ofFunctionalised NP

3) THERAPY- delivery of siRNA - release of drug compound- hyperthermic activation

of Nanocarrier whichtriggers drug release

=> leads to destruction

of tumour cells

4) THERANOSTICSStudy of combined approach :2 functionalities for diagnosisand therapeutic actionby Magnetic nanocarrier system

For example : - Hyperthermia = THERA - Magnetic NP + specific

antibody + electromagnetic field = NOSTICS

Tumour cells

I M A G I N G

S P 2 T o x i c o

l o g y

& B i o c o m p a

t i b i l i t y

L e a d e r : J R

C G A I K E R

, T A U

, H a m e l n , A

H A V A

, P H M A R

S P O P r o j e c

t M a n a g e m e n

t , D i s s e m i n a

t i o n

& E x p

l o i t a

t i o n

A l m a +

G A I K E R

SP1

NP Functionalspecifications

+ selectionLeader : LCPO

COLORITA FEYECON

INSTMNuovoProbe

ARGUS

SP3

Targeting& DiagnosisLeader : VC

TEIA RMSBLCPOINSTMLEITAT

SP5

TheranosticsLeader :

COLORITA

INSTMTAUTEIA

NuovoProbeLEITAT

SP4

Pro-TherapyLeader : INSTM

CICbioCOLORITA

LCPOPHMAR

TAU Argus

SP6

Efficiency & biodistributionLeader : GAIKER

JRC - TAU - HamelnPHMAR - CICBIO - LEITAT

Nanosystem

Selection

Nanosystem

Selection

Feedback system



Consortium

Communication and results dissemination areessential for the successful accomplishment of NANOTHER objectives, and these activities aimat generating an ef cient information ow bothwithin the consortium and also towards scienti ccommunities. Nanother partners aim to fully

exploit the results obtained, to communicate oncontributions made to European knowledge andscienti c excellence, as well as the value of thecollaboration on a Europe-wide scale, and thebene ts to EU citizens in general.

The diagnostic & drug-delivery system developedin NANOTHER will have a positive impact on thediagnosis & treatment of widespread diseases

such as cancer, and therefore on the quality of life of EU citizens in the medium term. Currently,diagnosis is often late and once a tumour hasbeen discovered, available treatments at presentare imperfect and the probability of cure is nothigh. Current treatments are highly toxic to

normal tissue and cause substantial loss of quality of life. NANOTHER will focus on diagnosisat cellular level which will mean earlier diagnosisand reduced diagnostic time so the treatmentcan be applied more rapidly and with reducedside effects. Another major break through willbe the application of combined diagnosis & therapeutic technology via innovative theranosticdevelopment combining magnetic nanocarriers

Acknowledgment The Nanother project is supported by the European Commission through the Seventh Framework Programme for Research & Development. The 4 year project will run from 1st September 2008 –31st August 2012.

Scienti c CoordinatorDr Pedro HEREDIA – Fundacion Gaiker - [email protected]

Dissemination ManagerProfessor Emo Chiellini - INSTM - [email protected]

Exploitation ManagerPilar Calvo – PHARMAMAR - [email protected]

Project ManagerDr Caroline ELSTON – AlmaCG - [email protected]

Communication & impact – a high priority or Nanother partners

www.nanother.eu

• TechnologicalEducational Instituteof Athens

• FEYECON

• Hameln

• NuovoProbe

• Joint Research Centre

University Research center

SME Consultancy

• INSTM• COLOROBBIA • Argus Chemicals

• Tel-Aviv University• Ahava

• Université Bordeaux2 - RMSB

• Institut PolytechniqueBordeaux - LCPO

• ALMA ConsultingGroup

• Pharmamar• Gaiker• CICbioGUNE• Vicomtech• LEITAT

nanother: integration of novel nanoparticle based technology for therapeutics and diagnosis of...

Documents